Clotting and bleeding are major causes of mortality and morbidity during high risk ECMO therapy that treats the “sickest of the sick” by infusing patients with oxygen-rich blood drawn from an ECMO circuit. One key component of an ECMO circuit is the oxygenator. As a clot develops in the oxygenator over time, the volume of oxygenated blood decreases and less oxygen-rich blood is delivered to the critically ill patient. If the clot gets large enough, the oxygenator will need to be switched out by the perfusionist as quickly as possible and replaced by one that will continue to oxygenate the blood.
Topics: ELSA Monitor
“The ELSA monitor provides an easy-to-use, non-invasive method to measure recirculation in VV ECMO without blood sampling.” SS Said, MD
The state-of-the-art Transonic® ELSA Monitor helps optimize and safeguard extracorporeal membrane oxygenation (ECMO) therapy in infants, children and adults by:
- Measuring true blood flow in ECMO circuits
- Quantifying recirculation in the ECMO circuit
- Detecting oxygenator clotting
With the ELSA, surgeons can place a cannula so that flow delivery is maximized. By maximizing flow delivery and minimizing recirculation, a perfusionist then has more time to change out the oxygenator if and when the ELSA identifies unacceptably high clot development within the oxygenator.
Knowing actual blood flow through the circuit at all times helps avoid catastrophic circuit failures in fragile ECMO patients. Kinks and circuit blockages can be immediately identified and corrected. When flow delivery is maximized, recirculation is minimized, and optimal cannula placement is achieved, the time a patient must be on ECMO is shortened. This translates into better outcomes and bottom line cost savings for an ECMO program.
Safeguard your ECMO program by using the Transonic ELSA Monitor.
1. Said MM et al, Children’s Hospital, Washington, D.C., “Influence of central hemodynamics on VV ECMO oxygen delivery in neonatal animal model,” J Neonatal Perinatal Med 2017.
Topics: ELSA Monitor